Clinical trials and research studies

NXDC-MEN-301: Subjects are being asked to participate in this study because they have a brain tumor, a meningioma, and surgery is recommended to remove it.  The sponsor of this clinical trial, NX Development Corp, has developed the study drug, Gleolan, an imaging agent that in some brain tumors, can make the tumors glow red-violet under a special blue light. This may make it easier for the study surgeon to identify the tumor and to remove it.  As part of the study, subjects will drink the Gleolan before your surgery.  The goal is to safely remove the tumor.

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.